{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-055041","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.726287+00:00","generated_at":"2026-06-03T04:34:59.269284+00:00","sec_items":["2.04","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NRx receives default notice on $6.5M note; reports promising NRX-101 trial data vs lurasidone","bullets":["Streeterville Capital alleges default on $11.02M convertible note; demands acceleration and repayment of at least $6,537,027.","Company disputes the claim, says spin-off of Hope Therapeutics is not a Fundamental Transaction, and will defend vigorously.","Phase 2b/3 trial: NRX-101 showed 33% advantage in sustained remission of suicidality vs lurasidone (not statistically significant at this sample size).","NRX-101 showed 75% advantage in relief from akathisia (P=0.076), a side effect linked to suicide; both signals met promising zone criteria.","Company plans 300-patient registrational trial; believes NRX-101 could be the first oral antidepressant to reduce suicide risk."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-055041","json":"https://secwatch.observer/filing/0001104659-24-055041.json","markdown":"https://secwatch.observer/filing/0001104659-24-055041.md","text":"https://secwatch.observer/filing/0001104659-24-055041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924055041/0001104659-24-055041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924055041/tm2413153d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T04:34:59.269284+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ff6afcf2266a4c31bac45776502da0cd2def17f","claim":"NRX Pharmaceuticals, Inc. faced acceleration on convertible notes of $11,020,000.00 with Streeterville Capital, LLC.","evidence_excerpt":"Note (the \"Note\") dated November 4, 2022 issued by NRX Pharmaceuticals, Inc., a Delaware corporation (\"Borrower\"), in favor of Lender, in the original principal amount of $11,020,000.00, as amended by that certain Amendment to Convertible Promissory Note dated March 30, 2023 (\"Amendment #1\"), that certain Amendment #2 to Convertible Promissory Note dated July","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924055041/0001104659-24-055041-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$11,020,000.00"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Event","value":"acceleration"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}